L-alanyl-L-glutamine


Concise Prescribing Info
Indications/Uses
As part of parenteral nutrition regimen in a hypercatabolic state.
Dosage/Direction for Use
Adult : IV Dosage is individualised according to severity of the catabolic state and amino acid/protein requirements. As 200 mg/mL solution for infusion: 300-500 mg/kg/day. Max: 500 mg L-alanyl-L-glutamine/kg/day; 2,000 mg amino acids/kg/day. Max duration of treatment: 3 weeks.
Dosage Details
Intravenous
Part of parenteral nutrition regimen
Adult: Dosage is individualised according to severity of the catabolic state and amino acid/protein requirements. In a hypercatabolic state: As 200 mg/mL solution for infusion: 300-500 mg/kg daily. The proportion of the amino acids supplied should not exceed approx 30% of the total amino acid supply. Max: 500 mg L-alanyl-L-glutamine/kg daily; 2,000 mg amino acids/kg daily. Max duration of treatment: 3 weeks.
Contraindications
Severe metabolic acidosis. Severe hepatic and renal impairment (CrCl <25 mL/min).
Special Precautions
Mild to moderate hepatic impairment. Pregnancy and lactation.
MonitoringParameters
Monitor serum electrolytes, osmolarity and bilirubin, water balance, acid-base status and LFTs (e.g. alkaline phosphatase, ALT/AST); signs and symptoms of hyperammonaemia.
Action
Description: L-alanyl-L-glutamine is used as a part of parenteral nutrition. In the body, it endogenously split into two amino acids, alanine and glutamine. The released amino acid flow as nutrients into their respective body pools and are metabolised according to the needs of the organism.
Synonym: N(2)-L-alanyl-L-glutamine, alanylglutamine.
Pharmacokinetics:
Excretion: Elimination half-life: 2.4-3.8 minutes.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. l-Alanyl-l-glutamine, CID=123935, https://pubchem.ncbi.nlm.nih.gov/compound/l-Alanyl-l-glutamine (accessed on Jan. 22, 2020)

Storage
Store below 25°C.
Any unused portions should be disposed of in accordance with local requirements.
References
Buckingham R (ed). Glutamic Acid. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/08/2018.

Fresenius Kabi New Zealand Limited. Dipeptiven Concentrate for Solution for Infusion data sheet 19 March 2012. Medsafe. http://www.medsafe.govt.nz/. Accessed 06/08/2018.

Joint Formulary Committee. Parenteral Nutrition Supplements. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/08/2018.

Disclaimer: This information is independently developed by MIMS based on L-alanyl-L-glutamine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in